CAC 0 takes a gut punch, ICD therapies cannot be surrogates for benefit, and two important trials from ESC are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I CAC 0
- LDL-C and CVD Risk With CAC Score 0 https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf497/8228645
II ICD Therapies
- Contemporary ICD Benefit https://www.jacc.org/doi/10.1016/j.jacep.2025.06.028
- PROFID Trial https://profid-project.eu/profid-ehra-trial/
- MADIT-RIT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1211107
- Declining Risk of Sudden Death in HF https://www.nejm.org/doi/full/10.1056/NEJMoa1609758
III Digit-HF
- DIGIT-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415471
- Digoxin–Mortality: Comparison in the DIG trial https://academic.oup.com/eurheartj/article/40/40/3336/5520008
IV POTCAST
- POTCAST trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509542
ESC Preview
IV HTN Guidelines
- New Blood Pressure Guidelines: 4 Things I Like and 2 Concerns https://www.medscape.com/viewarticle/new-blood-pressure-guidelines-4-thing-i-and-2-concerns-2025a1000m1x
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
